80
Participants
Start Date
August 1, 2022
Primary Completion Date
June 5, 2024
Study Completion Date
June 19, 2024
Orvepitant Maleate
Orvepitant tablets 30mg or 10mg
Placebo
Placebo tablets to match orvepitant 30mg and 10mg tablets
Temple University, Philadelphia
Jadestone Clinical Research, LLC, Silver Spring
University of Virginia Health System, Charlottesville
PulmonIx, LLC, Greensboro
American Health Research, Charlotte
Medical University of South Carolina, Charleston
Vanderbilt University Medical Center, Nashville
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
Loyola University Chicago, Maywood
Baylor University, Dallas
Clear Lake Health, Webster
National Jewish Health, Denver
University of Utah, Salt Lake City
University of Southern California, Los Angeles
University of California, San Francisco
Zuyderland Medical Centre, Heerlen
Sint Antonius Hospital, Nieuwegein
Erasmus University Medical Centre, Rotterdam
Isala Ziekenhuis, Zwolle
Royal Berkshire Hospital, Reading
Castle Hill Hospital, Cottingham
MAC Clinical Research, Prescot
Antrim Area Hospital, Antrim
Altnagelvin Area Hospital, Londonderry
Churchill Hospital, Headington
Perth Royal Infirmary, Perth
Royal Infirmary of Edinburgh, Edinburgh
MAC Clinical Research, Barnsley
MAC Clinical Research, Leeds
Heartlands Hospital, Birmingham
Royal Papworth Hospital, Cambridge
Royal Devon and Exeter Hospital, Exeter
Guy's Hospital, London
MAC Clinical Research, Manchester
Nottingham City Hospital, Nottingham
Southampton General Hospital, Southampton
Lead Sponsor
Collaborators (1)
Pharm-Olam International
INDUSTRY
Nerre Therapeutics Ltd.
INDUSTRY